Exploring the potential of nutraceutical to combat gliomas: focus on mIDH2 protein
Somatic transformations in the key catalytic residues of the Isocitrate Dehydrogenase (IDH) enzyme assist in the onset of distinct malignancies including glioma. Currently, enasidenib is the FDA-approved drug used to target IDH2 protein. However, the use of enasidenib as a plausible mIDH2 inhibitor...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Physics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphy.2024.1345834/full |